TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06712355: Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Sponsor: BioNTech SE · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 621 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,051,508

Rescue Site Savings

+$3,345,804

Unlock Full NCT06712355 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06712355 Rescue Dossier →